New Treatment for MS Drastically Reduces Symptoms
Good news! A trial of the drug Ofatumumab has shown to significantly outperform existing treatments for relapsing-remitting-multiple sclerosis (RRMS). The trial consisted of more than 900 patients who received a monthly injection of the drug for an average of 19 months, and were compared against teriflunomide – a widely prescribed drug to treat RRMS. Ninety percent of the participants in the trial reported no MS attacks after the first year of treatments.
Ofatumumab is already approved to treat a form of white blood cell cancer, and works by suppressing the CD20 protein that is present on the B-Cells of the immune system. Multiple Sclerosis is an auto-immune disease that causes the bodies immune system to turn on itself. The suppression of the CD20 protein could help with the frequency of attacks but leaves the body more vulnerable to other threats.